New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 20, 2013
09:13 EDTTHLDThreshold Pharmaceuticals upgraded to Overweight from Neutral at Piper Jaffray
Piprer Jaffray upgraded Threshold Pharmaceuticals citing its TH-302 opportunity. Price target raised to $10 from $5.
News For THLD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 18, 2015
07:01 EDTTHLDThreshold enters into definitive co-promotion agreement with Merck
Threshold Pharmaceuticals (THLD) announced that it finalized a definitive Co-Promotion Agreement for evofosfamide with Merck (MRK) pursuant to the companies' License and Co-Development Agreement entered into on February 2, 2012. Under the terms of the License and Co-Development Agreement, Threshold may co-promote evofosfamide in the U.S. subject to FDA approval of evofosfamide. Evofosfamide is Threshold's investigational hypoxia-activated prodrug, which is currently the subject of two fully enrolled Phase 3 clinical trials in advanced soft tissue sarcoma and advanced pancreatic cancer for which Threshold expects to announce top-line data around the end of 2015. Under the commercial leadership of Merck KGaA, Darmstadt, Germany, the terms of the License and Co-Development Agreement give Threshold the right, at its own cost, to field and be responsible for its own sales force in collaboration with Merck KGaA, Darmstadt, Germany's sales force in the U.S. pursuant to the terms of the new Co-promotion Agreement. Merck KGaA, Darmstadt, Germany remains responsible for all other commercial and medical affairs functions associated with the launch and promotion of evofosfamide. The development milestone payment and royalty payment portions of the License and Co-Commercialization Agreement remain the same. To date Threshold has received upfront and milestone payments of $110 million and can earn additional potential milestone payments of up to $440M.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use